Immunis, a clinical-stage biotech company developing a first-in-class multi-active biologic, announced the launch of its new logo and brand identity. The rebrand reflects the company’s scientific focus on multi-pathway biology and its mission to improve muscle function, metabolic health, and overall healthspan.

Immunis’ platform is built on the understanding that age-related and chronic diseases are driven by interconnected biological pathways. Unlike conventional therapies that target a single mechanism, IMM01-STEM is a complex biologic composed of regenerative factors that act across hundreds of signaling pathways. The updated logo is inspired by the coordinated activity of secreted signaling factors and cellular pathways that drives functional improvements in muscle and metabolic health. It represents a shift from a traditional single-target mindset to a systems-based approach that mirrors the complexity of human biology and aging.

The broader brand identity introduces imagery centered on movement, strength, and function, with a refined color palette that provides a natural and warm energy that mirrors healthy aging.

“Muscle health is one of the most important and overlooked determinants of healthy aging,” said Dr. Hans Keirsted, Chairman of Immunis. “It supports physical independence, metabolic resilience, recovery from illness, and overall vitality. Our new brand identity captures both the biological foundation of our platform and our commitment to developing therapies that help people live stronger, healthier lives.”

The rebrand comes at a pivotal moment for Immunis, following recent clinical progress and organizational growth. Earlier this year, the company shared interim data from a Phase 2 clinical study using its IMM01-STEM biologic, demonstrating preservation of muscle mass and improvements in gait speed in obese, sarcopenic adults. These findings further position Immunis at the forefront of a growing category of “cell-free” regenerative therapies designed to deliver the benefits of stem cell biology without the complexities associated with cell-based treatments.

“As our science advances, it is critical that our brand clearly communicates what makes Immunis different,” shares Senior Scientific Communications Manager, Dr. Karissa Munoz. “This evolution aligns our visual identity with our scientific leadership and our long-term vision to redefine how age-related diseases are treated.”

Looking ahead, Immunis plans to expand its manufacturing capabilities and advance additional Phase 2 clinical programs targeting muscle and metabolic function across multiple indications.

About Immunis

Immunis is a clinical-stage biotechnology company developing multi-active biologics to treat the various manifestations of age-related diseases and immune dysregulation. The investigational product line leverages Immunis’ leading-edge capabilities in stem cell technology to deliver a product of all-natural, all-human immune modulators in their natural physiological concentrations. For additional information about Immunis’ programs, please visit Immunisbiomedical.com.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations, and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry, which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Press Contact

 Shira Derasmo, Cuttlefish Communications

917-280-2497 | shira@cuttlefishpr.com

Investor Relations Contact

Mark Cabato, Chief Business Officer, Immunis, Inc.

mark@immunisbiomedical.com